Non-suppressible secondary hyperparathyroidism in chronic progressive renal disease  by Slatopolsky, Eduardo et al.
Kidney International, Vol. 1 (1972), p. 38—46
Non-suppressible secondary
hyperparathyroidism in chronic
progressive renal disease
EDUARDO SLATOPOLSKY, W. ERNEST RUTHERFORD, PHILLIP E. HOFFSTEN,
IVAN 0. ELKAN, HARVEY R. BUTCHER, and NEAL S. BRICKER
Renal Division, Department of Internal Medicine and the Department of Surgery, Washington University
School of Medicine, St. Louis, Missouri
Non-suppressible secondary hyperparathyroidism in chronic
progressive renal disease. Secondary hyperparathyroidism is a
frequent, and almost universal, concomitant of advancing
chronic renal disease. When renal failure is of long standing,
the degree of secondary hyperparathyroidism may be quite
marked. Under such circumstances, short-term elevation of
serum calcium concentration does not lead to a decrease in
radioimmunoassayable parathyroid hormone to normal levels
or to an increase in tubular reabsorption of phosphate (TRP) to
normal levels. However, in the majority of patients sustained
elevation of serum calcium for periods in excess of two weeks
will lead to an increase in TRP to values in excess of 80%. A
minority of patients, however, will not respond to phosphate
depletion and elevation of serum calcium in the typical manner.
Such patients fall into the category of so-called "autonomous" or
'tertiary" hyperparathyroidism. The present studies demonstrate
that patients with non-suppressible or poorly suppressible
secondary hyperparathyroidism become readily suppressible
following removal of approximately 80% of their parathyroid
tissue. That the same tissue present in smaller amounts could be
suppressed by a stimulus which had proved ineffectual when the
larger mass of gland was present suggests that autonomy may be
apparent rather than real and may relate to the mass of the
parathyroid hormone secreting tissue present.
Hyperpararhyroidisme secondaire non-suppressible de i'm-
suffisance rénale chronique. L'hyperparathyroidisme secondaire
est une complication frequente, et, sans doute, habituelle de
l'insuffisance rbnale progressive. En cas d'insuffisance rénale
de longue durée, le degré d'hyperparathyreoidisme secondaire
pent être d'une sévèrité marquee. Dans ces circomstances,
une breve élévation du taux du calcium sérique ne suffit pas a
normaliser l'hyperconcentration d'hormone parathyroid ienne
dans Ic sang ou l'hyporeabsorption tubulaire du phosphore.
Mais une élévation prolongCe, pendant deux semaines ou
davantage, du calcium serique, en general, ramene Ia réabsorp-
tion tubulaire du phosphore a des valeurs dépassant 80%.
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Toutefois, une minorité de malades ne répondent pas d'une
manière typique a une elevation du calcium sérique et a une
carence phosphoree. Ces malades souffrent d'un hyperpara-
thyroidisme non-suppressible, vautonome>> ou ntertiairen. Nos
recherches ont dbmontré que 4 malades sur 5, atteints d'hyper-
parathyroidisme secondaire non-suppressible, étaient facilement
susceptibles de suppression aprés ablation d'environ 80% de leur
tissu parathyroidien. Le fait qu'une petite quantité du même
tissu soit suppressible a l'aide d'un stimulus qui etait inefficace
lorsque Ia masse glandulaire était plus grande, suggere l'existence
d'une autonomie endocrine plus apparente que reelle, fonction
de Ia masse du tissu sécrétant I'hormone parathyroidienne.
The interrelationships between nephron destruction
in advancing renal disease and hyperfunction of the
parathyroid glands have become the focus of intense
and increasing interest [1—14]. We recently have pre-
sented the view that secondary hyperparathyroidism
in chronic renal disease represents, at least to a major
degree, a manifestation of an adaptive response of the
control system governing the renal excretion of phos-
phate [15—16]. Tn essence, the fewer the number of
functioning nephrons surviving, and the lower the
glomerular filtration rate, the greater must be the rate
of phosphate excretion per nephron if external phos-
phate balance is to be preserved on a relatively normal
intake of phosphorus. Parathyroid hormone (PTH)
inhibits phosphate reabsorption by the renal tubular
epithelial cells and thereby serves to promote phos-
phaturia. It thus is appropriate that parathyroid hor-
mone levels rise as the nephron population diminishes.
However, in chronic uremia of long duration, PTH
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concentrations may reach extremely high levels (17—18]
and the continued presence of severe hyperparathy-
roidism may contribute importantly to the skeletal
lesions which occur in uremic patients. Reduction of
PTH levels thus may represent an important thera-
peutic goal. Evidence now is accumulating that sus-
tained elevation of the serum calcium concentration
will decrease the degree of hyperparathyroidism in
many patients with chronic uremia [9—14]. However in
some instances, the parathyroid glands seem to escape
from the feedback suppression normally induced by
elevation of serum ionized calcium concentrations. The
term autonomous or "tertiary" hyperparathyroidism
has been employed to describe the latter state [19—22].
In the present studies, efforts were made to further our
understanding of the nature of the state of reduced
feedback suppressibility of parathyroid function in
chronic uremia.
Observations are presented on a group of patients
with far-advanced chronic uremia and secondary
hyperparathyroidism. Special attention is given to five
patients in whom feedback regulation of parathyroid
function appeared to be substantially diminished or
lost. The data suggest that decreased suppressibility is
an expression of an advanced state of secondary
hyperparathyroidism, but that it does not necessarily
reflect the development of a true autonomous endo-
crine state.
Methods
Observations on the feedback suppressibility of
parathyroid function have been performed on 18
patients with chronic uremia. Thirteen patients ulti-
mately responded appropriately to the sustained eleva-
tion of the serum calcium concentration (detailed
results of six of these patients have been described
previously [9]). Five of the 18 patients either had a
limited response or failed to respond to sustained
hypercalcemia. The observations on these five indi-
viduals constitute the subject of this report. Each of
these patients was admitted to the Clinical Research
Center during the period of study. The dietary intake
of phosphorus was maintained at 600± 100 mg/day
unless otherwise indicated. Serial renal function studies
were performed at the intervals indicated below.
The first set of studies, designated as control in the
text and tables, was performed within several days of
admission to the hospital. Thereafter, a phosphate-
binding gel (aluminum carbonate gel') was admin-
istered in a dosage of 40 to 60 ml four times daily in
order to reduce the plasma phosphate concentrations
to normal or subnormal levels. The dietary intake of
phosphorus also was diminished to approximately
450 mg/day. After this regimen had been in force for
at least 14 days, the second set of clearance studies
was performed. Thereafter, the patients were given
200,000 to 300,000 units of vitamin D daily and 2 to 4 g
of calcium gluconate four times daily. The aluminum
carbonate gel and low phosphorus diet were continued.
Serum calcium concentrations rose in all patients and
were maintained between 11 and 13 mg/100 ml for
periods of up to two months. The patients were closely
supervised during this interval so as to prevent pro-
gressive hypercalcemia and serum phosphate con-
centrations were maintained below 3 mg/100 ml. TL
third set of studies was performed after the serum
calcium concentration had been elevated for at least
4 weeks. Each of the patients then was subjected to
parathyroidectomy. In four of the five patients, four
parathyroid glands were identified at surgery, and
three glands were removed completely, and an esti-
mated 50% of the fourth gland was removed. In the
fifth patient (T. D.) only three glands were identified
at surgery and two and a half were removed. From 10
to 44 days after recovery from the surgical procedure,
with the patients still on vitamin D and calcium, the
final set of clearance studies was performed.
Glomerular filtration rate (GFR) was measured by
the clearance of inulin and phosphate clearance was
measured simultaneously during each clearance period.
At least three clearance periods of 20 to 30 minutes in
duration were obtained in each study. In some studies,
after completion of the third clearance period, 250 units
of parathyroid hormone extract2 were given intra-
venously over a period of 5 to 10 minutes and one
unit/minute was infused in a 5% dextrose and water
solution at a rate of 2 mI/minute. Forty-five to sixty
minutes were allowed for equilibration following which
three additional clearance periods were obtained. In
all clearance studies, urine was collected using an
indwelling bladder catheter. At the end of each period,
the bladder was washed with sterile distilled water and
rinsed with air. Rigorous asepsis was employed in
performing the catheterizations and clearance maneu-
vers. Bacitracin-neomycin ointment was used as a
lubricant and at the end of each study the bladder was
irrigated with 200 ml of 1 % neomycin solution. Urine
cultures were obtained at the end of each study and
1 Basaljel® 2 Parathyroid®-Lilly
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repeated after several days. None of the patients
developed a urinary tract infection. Blood was collected
at the mid-point of each clearance period through an
indwelling venous catheter. Additional details of the
experimental procedure have been described previ-
ously (9). Jnulin was measured by the method of Roe,
Epstein and Goldstein [23], and phosphate by the
method of Gomori [24]. Calcium was analyzed on an
atomic absorption spectrophotometer (IL Model 53)
and the tubular reabsorption of phosphate was cal-
culated in the conventional manner.
Results
Sequential studies on one of the patients with non-
suppressible secondary hyperparathyroidism are pre-
sented in Fig. 1. GFR was 4.5 mi/mm. During the
control clearance studies, while on a 600 mg/day
phosphorus intake, the patient was hyperphosphatemic
and hypocalcemic. The TRP was 22.9%. Aluminum
carbonate gel administration then was initiated and
phosphorous intake was reduced to 450 mg/day. After
two months on this regimen the serum phosphate
concentration had decreased from 7.9 to 4.5 mg/l00 ml
and the calcium concentration had increased from 8.4
to 9 mg/l00 ml. However, TRP failed to increase (the
P04 Co
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Fig. 1. The effects of phosphate depletion and vitamin D and
calcium administration on the tubular reabsorption of phosphate
(TRP) in a representative patient with non-suppressible hyper-
parathyroidism.
value, as shown in Fig. 1, actually decreased from
22.9 to 14.6 %). Thereafter the patient was started on
vitamin D and calcium as described in the Methods
section. Plasma calcium values were maintained be-
tween 11 and 13 mg/l00 ml and after four weeks clear-
ance studies were repeated. On the day of study, the
plasma calcium concentration was 12.4 mg/l00 ml and
the phosphate concentration was 1.3 mg/lOO ml. De-
spite the presence of sustained hypercalcemia (and hypo-
phosphatemia), the fraction of filtered phosphate reab-
sorbed remained strikingly depressed, i. e., TRP =39%.
In contrast to this response is the pattern found in
the majority [13 of 18] of patients with chronic renal
disease whom we have studied. The results of a similar
sequence of studies, performed on a representative
patient with chronic uremia and "suppressible" sec-
ondary hyperparathyroidism, are shown in Fig. 2.
Glomerular filtration rate was 2.4 mI/mm. The patient
was hyperphosphatemic and hypercalcemic at the time
of the control clearance studies, and the value for
TRP was 28 %. With reduction of the serum phosphate
concentration from 7.7 to 3.7 mg/lOO ml, the plasma
calcium concentration rose spontaneously from 8.5 to
9.1 mg/lOO ml. The TRP, however, remained maxi-
mally depressed (14%). Vitamin D and calcium ad-
P04 -Ca
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Fig. 2. The effects of phosphate depletion and vitamin D and
calcium administration on tubular reabsorption of phosphate in
a representative patient with suppressible hyperparathyro-
idism.
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ministration then were initiated. Three weeks later,
with the plasma calcium concentration at 11.1 mgI
100 ml, TRP had risen to 89 %.
Table 1 summarizes the results of the serial studies
performed on all five patients with non-suppressible
or poorly suppressible hyperparathyroidism. In the
control studies GFR for the group ranged from 2.8
to 19.0 mI/mm with an average of 9.1 mI/mm. The
control values for TRP ranged from 16.3 to 22.9%
with a mean of 19.3%. Plasma phosphate concentra-
tions ranged from 3.9 to 16.7 mg/100 ml with a mean
of 7.9 mg/l00 ml. Serum calcium concentrations
ranged from 5.8 to 10.1 mg/l00ml with a mean of
8.5 mg/l00 ml. The administration of parathyroid
hormone extract failed to decrease the TRP appreciably
in any of the patients; the greatest change was seen in
the patient with the highest GFR where the value for
TRP fell from 22.6 to 13.7%. For the group the mean
change was from 19.3 to 17.7%. After the administra-
tion of aluminum carbonate gel and diminishing the
phosphorous intake, plasma phosphate concentration
fell to a mean of 2.8 mg/ 100 ml and plasma calcium
concentration increased to 10.3 mg/l00 ml. However,
the mean value for TRP increased only to 27.8%. The
final studies shown in Table 1 depict the effects of the
administration of vitamin D and calcium for periods
Table 1
Effects of decreasing plasma phosphate concentrations and sustained elevation of calcium
with non-suppressible hyperparathyroidism a
in five patients
Patient Condition GFR
mi/mm
Cp04
mi/mm
TRP
%
Pp04
mg/lOO ml
Ca
mg/JOO ml
G. K. a) Control
PTH
6.1
5.5
5.1
4.5
16.3
18.6
5.6
4.9
8.4
8.5
b) P04depletion 6.8 6.1 11.1 1.4 10.4
c) Vit. D+Ca 6.3 3.0 53.2 1.6 11.8
T. D. a) Control
PTH
2.8
2.7
2.3
2.1
17.4
22.8
16.7
16.3
5.8
6.7
b) P04depletion 3.5 2.5 29.9 4.8 11.0
c) Vit. D+Ca 3.1 2.0 33.9 2.6 12.1
C. C. a) Control
PTH
19.0
19.7
14.7
17.0
22.6
13.7
5.2
4.9
10.0
10.2
b) P04 depletion 14.4 7.3 49.2 2.4 10.1
c) Vit. D+Ca 16.7 6.5 61.3 1.8 12.4
C. B. a) Control
PTH
5.4
4.8
4.1
4.0
22.9
17.8
7.9
7.5
8.4
8.5
b) P04 depletion 4.2 3.6 14.6 4.5 9.0
c) Vit. D+Ca 4.3 2.6 39.0 1.3 12.4
W. S. a) Control
PTH
12.4
11.5
10.4
9.7
17.1
15.6
3.9
3.8
10.1
10.2
b) P04 depletion 11.1 7.3 34.2 1.2 11.1
c) Vit. D+Ca 10.3 8.2 20.4 2.1 12.9
Mean a) Control
PTH
9.1
8.9
7.3
7.5
19.3
17.7
7.9
7.5
8.5
8.8
b) P04 depletion 8.0 5.4 27.8 2.8 10.3
c) Vit. D+Ca 8.1 45 41.6 1.9 12.3
GFR, glomerular filtration rate; P,04, plasma phosphate concentration; RCa' plasma calcium
tion of phosphate; Cr04, clearance of phosphate; PTH, parathyroid hormone.
a All results are the average of three or more clearance periods.
concentration; TRP, tubular reabsorp-
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of up to two months. At the time of study the plasma
calcium concentration averaged 12.3 mg/100 ml and
the mean value for plasma phosphate concentration
was 1.9 mg/100 ml. The mean value for TRP increased
only to 41.6% and the highest value observed was
61.3%.
Fig. 3 compares the changes in TRP in the group of
five patients with diminished suppressibility with a
group of thirteen patients with chronic renal disease
and "suppressible" hyperparathyroidism. In the latter
group, GFR averaged 5.9 mI/mm versus the mean
value of 9.1 mI/mm in the patients with non-suppres-
sible hyperparathyroidism. In the suppressible group
TRP rose from a control value of 14% to a mean value
of 87% (sE± 1.96) after only two to three weeks of
vitamin D and calcium administration. On the other
hand, in the patients with diminished suppressibility,
despite the more prolonged elevation of plasma calcium
concentration, the rise in TRP was substantially and
significantly less (P<0.00l).
Each of the five patients with "non-suppressible"
secondary hyperparathyroidism was subjected to para-
thyroidectomy as indicated in the Methods section and
studies were then repeated from 10 to 44 days later.
The results are shown in Figures 4 and 5. In Fig. 4,
the values for TRP from the control studies are
compared with the values observed postoperatively.
The mean control value for TRP was 19.3% versus a
mean value of 85% in the post-parathyroidectomy
state. Serum calcium values averaged 8.5 mg/100 ml
in the control studies and 11.1 mg/100 ml (range:
10.7 to 11.3 mg/l00 ml) in the post-parathyroidectomy
studies. TRP failed to increase in only one of the five
patients (T. D.). This is the patient in whom only three
glands were identified at surgery and two and one-half
were removed .
Fig. 4 also demonstrates the fact that the post-
parathyroidectomized patients in whom TRP values
had risen strikingly responded to the administration of
parathyroid extract with a marked decrease in levels
of TRP. This responsiveness is to be contrasted with
the change in TRP from a mean value of 19.3% to
This patient's clinical course was characterized by persistence
of secondary hyperparathyroidism as evidenced by continuing
bone disease, increasing alkaline phosphatase concentrations,
and high levels of radioimmunosable PTH in the blood.
SECONDARY HYPERPARAfl-IYROIDISM
SUPPRESSIBLE
In I3)
ic
Vit D+Ca
NON SUPPRESSIBLE
(n'5)
CONTROL Vit. D + Co
TRP
Fig. 4. Changes in tubular reabsorption of phosphate during
control studies and after parathyroidectomy in 5 patients with
nonsuppressible or poorly suppressible hyperparathyroidism.
Fig. 3. Tubular reabsorption of phosphate during control
studies and after vitamin D and calcium administration in a
group of 13 patients with suppressible hyperparathyroidism and
in 5 patients with non-suppressible or poorly suppressible
hyperparathyroidism.
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Fig. 5. Tubular reabsorption of phosphate during maximum
suppression achieved by vitamin D and calcium administration
and after parathyroidectomy in 5 uremic patients with non-
suppressible or poorly suppressible hyperparathyroidism.
17.7 % following the administration of parathyroid
extract in the control studies. In Fig. 5, the values for
TRP following the maintenance of sustained hyper-
calcemia in the "non-suppressible" patients are com-
pared with the values obtained following parathy-
roidectomy. Although the mean value for serum
calcium concentration was 12.3 mg/100 ml prior to
parathyroidectomy, and 11.1 mg/100 ml after para-
thyroidectomy, the degree of suppression was strik-
ingly greater after removal of parathyroid tissue in
four of the five patients.
Discussion
One of the more intriguing relationships observed in
patients with chronic progressive renal disease is an
increase in the secretory function of the parathyroid
glands that accompanies the advancing destruction of
nephrons. Secondary hyperparathyroidism represents
not only a highly consistent concomitant of advancing
chronic renal disease, but the more severe and long
standing the renal failure, the more marked the hyper-
parathyroidism appears to be [18]. Recent evidence
suggests that hyperparathyroidism may begin with the
onset of a nephron destroying process and progress
pan passu with the decline in glomerular filtration
rate [16]. A major factor in the pathogenesis of the
secondary hyperparathyroidism may be a transforma-
tion in the control system governing the renal excretion
of phosphate. To maintain external phosphate balance,
as the nephron population and GFR diminish, the rate
of phosphate excretion per residual nephron must
increase. Increasing concentrations of circulating para-
thyroid hormone appear to contribute to this pro-
gressive phosphaturia per nephron until late in the
course of disease. Two other factors unrelated to the
phosphate control system may also play a part in the
evolution and progression of secondary hyperpara-
thyroidism: I) the development of vitamin D resistance
could contribute to a decrease in ionized calcium con-
centration in the serum by impairing enteric absorption
of calcium [25—29]; 2) in advanced renal disease when
sustained hyperphosphatemia occurs, the elevated
serum phosphorous concentration per se could con-
tribute to a decrease in ionized calcium and thus lead
to further stimulation of PTH secretion.
In long-standing chronic renal disease, not only does
the level of parathyroid hormone become very high
[14—18], but the mass of parathyroid tissue charac-
teristically is quite large [30—31]. It is in this setting
that, in some instances, the parathyroid glands seem
to escape from the feedback suppression that normally
attends an increase in the serum concentration of
ionized calcium. Characteristically, in chronically
uremic patients, short-term elevation of the serum
calcium concentration by calcium infusion, results in
only moderate and incomplete suppression of para-
thyroid hormone release (as judged either by changes
in the values for tubular reabsorption of phosphate
[32—33] or in radioimmunoassayable PTH levels [18].
An example of the degree of suppressibility in a patient
with chronic glomerulonephritis and a glomerular
filtration rate of 5 ml/min is shown in Fig. 6. Although
the levels of PTH decreased in response to elevation of
the serum calcium concentration, they remained very
much above the normal range. On the other hand, if
the concentration of calcium in the serum is maintained
above normal for a period in excess of two to three
weeks, the majority of patients with long-standing
secondary hyperparathyroidism have been found to
exhibit marked suppression of parathyroid hormone
activity (9). Of 18 patients in whom we have maintained
serum calcium levels elevated for two or more weeks,
values for TRP rose strikingly in thirteen. The mean
value for TRP for this group was 87%. However, in
the other five patients, the response was different.
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, 1CALCIUM INFUSION 3MG/KG/HR
Fig. 6. Serum levels of parathyroid hormone (PTH) in a uremic
patient during the intravenous administration of calcium given
at the rate of 3 mg/kg/h over a period of six hours.
Despite the fact that serum calcium concentrations
were maintained between 11 and 13 mg/100 ml for an
average of 6 weeks, the maximum value for TRP was
61 % (at a serum calcium of 12.4 mg/lOO ml), and the
mean value for the five patients was 4l.6%. The
possibility thus exists, that in these five patients, the
hypertrophied and hyperplastic parathyroid glands
escaped from normal feedback control mechanisms
and acquired a state of relative or true autonomy. The
present data make this explanation unlikely.
The evidence against autonomy seems quite com-
pelling. In four of the five patients, approximately three
and one-half of four parathyroid glands were removed
surgically4. Thereafter the residual parathyroid tissue
was readily suppressed by a modest elevation of serum
calcium concentrations. Presumably the remaining
chief cells had the same structural and functional
characteristics as the resected chief cells; and were the
initial mass of parathyroid gland to have been auto-
nomous, the residual mass should have remained
Histologically the resected glands all were characterized by
chief cell hyperplasia.
autonomous. The fact that the residual tissue could be
suppressed readily indicates the persistence of normal
feedback control characteristics of the parathyroid
hormone secreting cells.
The explanation for the limited degree of suppressi-
bility before subtotal parathyroidectomy and the ready
suppressibility following parathyroidectomy is not
entirely obvious. However, it seems likely that a
major factor in the different degrees of responsiveness
relates to the quantity of secretory cells before and
after surgery. Prior to parathyroidectomy the degree
of hypertrophy and hyperplasia of the parathyroid
glands was such that even if each secretory cell
responded to hypercalcemia with a striking decrease
in the rate of hormone secretion, the composite rate
of secretion from the suppressed cells still might have
been sufficiently great to produce marked inhibition
of phosphate reabsorption by the tubular epithelial
cells. However after the mass of parathyroid tissue had
been decreased by at least 80%, the same degree of
suppression per cell might have led to a decrease in
circulating PTH that could readily be detected bio-
logically i.e., by measurement of TRP.
It also is possible that the PTH secretion rate per
unit of cell mass was not suppressed before para-
thyroidectomy by elevation of the serum calcium con-
centration and that it remained at the same level after
parathyroidectomy. In this instance simply the de-
crease in mass would result in a sufficient decrease in
circulating hormone levels to allow for the observed
increase in TRP. Somewhat against this explanation,
however, are the data reported by Reiss et al [18] on a
patient with non-suppressible secondary hyperpara-
thyroidism. Following subtotal parathyroidectomy
PTH levels remained elevated for over three days and
then, in response to the administration of vitamin D
and calcium, fell to within the normal range. Another
factor weighing against this second thesis is that if
vitamin D and calcium are not administered to "non-
suppressible patients" after parathyroidectomy, TRP
values remain low.
The present observations suggest that the failure
of a patient with long-standing and severe secondary
hyperparathyroidism to respond to phosphate deple-
tion and sustained elevation of serum calcium by a rise
in TRP to levels in excess of 80% does not necessarily
imply the existence of autonomy of parathyroid
function. Indeed, the fact that in four of five patients
with diminished to absent suppressibility, feedback
responsiveness was restored by removal of the great
majority of their parathyroid tissue would speak
1:
H
TIME (HOURS)
Non-suppressible secondary hyperparathyroidism 45
strongly against the consistency of true autonomy in
this setting. If a truly autonomous state of parathyroid
hormone secretion does occur in patients with ad-
vanced chronic renal disease, the possibility must be
considered that the hyperparathyroidism antedated
the development of renal disease rather than occurring
in consequence of the disease. When patients with
pre-existing non-suppressible adenomata are excluded,
the occurrence of true autonomy as a long range
transformation in parathyroid function in chronic renal
disease may represent a very rare phenomenon.
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